AudiologyOnline Phone: 800-753-2160


Neuromod Devices - Your Partner for Tinnitus - September 2021

GN Otometrics Launches ICS Balance Platform

Share:

Portable system for measuring postural sway

Schaumburg, Ill., April, 2008 - GN Otometrics, the world leader in hearing and balance diagnostic systems, is proud to introduce the ICS Balance Platform which utilizes a fixed force plate to measure the vertical force put forth by the patient's feet and assess the patient's amount of postural sway.

 

 

 


The ICS Balance Platform is offered in 3 versions: Balance Screener, Balance Trainer and Full Clinical version.

Balance Screener with the mCTSIB and LOS evaluates sensory contributions used for balance control. Modified Clinical Test of Sensory Interaction and Balance (mCTSIB) provides objective measurement of sway when the patient is placed in 4 sensory conditions that were developed based on normal daily activities. Limits of Stability provides an objective measure of displacement of the patient's center of gravity when the patient is asked to lean to 8 different postural positions.

Balance Trainer provides interactive training exercises with recorded voice-over instructions and real-time monitoring of movement for the patient leading to better balance control.

Full Clinical offers all the functionality of the Balance Screener and Balance Trainer with the addition of a custom balance assessment which gives the tester the ability to define any condition used for evaluation on the force plate.

The Balance Platform force plate is compact, portable, USB powered, with easy-to-use software and a comprehensive report.

Copenhagen-based GN Otometrics is the world's leading manufacturer of hearing and balance instruments and software. The company has solutions that range from infant-screening applications and audiologic diagnostics, to balance testing and hearing-aid fitting.

More information about GN Otometrics can be found at www.otometrics.com or the GN Otometrics Web Channel on Audiology Online.

 

 

Rexton Reach - April 2024

Our site uses cookies to improve your experience. By using our site, you agree to our Privacy Policy.